Research Article
Clinical Efficacy of Xueshuantong plus Urokinase in the Treatment of Sudden Deafness

Yanling Wang,1 Jian Wang,1 and Xiulan Chen2

1South China Hospital affiliated to Shenzhen University, The ENT Department, Shenzhen 518100, China
2The ENT Department, Qinghai Provincial People’s Hospital, Xining, Qinghai 810007, China

Correspondence should be addressed to Xiulan Chen; abenwo@21cn.com

Received 15 April 2022; Revised 25 May 2022; Accepted 30 May 2022; Published 29 June 2022

Academic Editor: Xiaonan Xi

Copyright © 2022 Yanling Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate the clinical effect of Xueshuantong combined with urokinase in the treatment of sudden deafness.

Methods. A total of 90 patients with sudden deafness who were treated in South China Hospital affiliated to Shenzhen University from June 2019 to August 2020 were recruited and assigned (1:1) into the control group (n = 45, urokinase) and the experimental group (n = 45, Xueshuantong plus urokinase) according to the different treatment methods. The clinical treatment effect, the degree of tinnitus, the average auditory valve of the damaged frequency, and the changes in hemorheology (plasma viscosity, whole blood high-shear reduced viscosity, whole blood low-shear reduced viscosity, hematocrit, and fibrinogen) were compared between the two groups of patients.

Results. The treatment with urokinase and Xueshuantong injection in the experimental group resulted in a significantly higher clinical treatment effect when compared with the treatment in the control group (P < 0.05). After treatment, the degree of tinnitus and the average auditory valve of the damaged frequency in the experimental group were significantly lower than those in the control group (P < 0.05). The levels of hemorheology (plasma viscosity, whole blood high-shear reduced viscosity, whole blood low-shear reduced viscosity, hematocrit, and fibrinogen) in the experimental group after treatment were significantly lower than those in the control group (P < 0.05).

Conclusion. The clinical effect of Xueshuantong combined with urokinase in the treatment of patients with sudden deafness is remarkable, and it can effectively improve the hearing level and hemorheology-related indexes of patients, and it thus merits clinical application.

1. Introduction

Sudden deafness is one of the common diseases of otolaryngology, and it falls into the category of sudden sensorineural hearing loss [1]. The main manifestations of the disease are deafness, tinnitus, earplugs, nausea, and dizziness [2], greatly compromising the patient’s daily life [3]. Though clinical cause of the disease is still unclear, several contributors such as virus infection theory, circulatory disorder theory, and immune theory have been identified [4]. At present, clinical-related research believes that the pathogenesis of sudden deafness is mainly related to viral infection, blood circulation disorder, eardrum labyrinth rupture, and autoimmune function, among which the theory of ear microcirculation has been widely recognized by the academic community [5]. The blood of the inner ear mainly comes from the labyrinthine artery of the human body. Since this artery has no collateral circulation, once thrombosis or vasospasm occurs, it would lead to ischemia, hypoxia, and microcirculation disturbance in the patient’s ear, which further damages the inner ear and even causes irreversible deafness [6]. A large number of clinical studies have shown that vascular disease plays a very important role in sudden deafness, and systemic dysfunctions such as coagulation and fibrinolysis in the labyrinthine arteries often contribute a lot to sudden deafness [7]. Therefore, improving the inner ear microcirculation of patients is of great significance to minimize the possibility of sudden deafness [8].

Urokinase is one of the commonly used drugs for the clinical treatment of patients with sudden deafness [9]. As a thrombolytic drug, it can act well on the endogenous fibrinolytic system and catalyze the cleavage of plasminogen...
Both groups were treated for 1 month. Of 5% glucose injection via an intravenous drip, 1 time/d. Group Co., Ltd.; approval number: Z20025652) with 500ml (manufacturer: Guangxi Wuzhou Pharmaceutical experimental group were given 450mg Xueshuantong injection (H44024035) [9] with 100ml of normal saline, via intravenous infusion within 30 minutes, once a day. On the basis of the treatment in the control group, the patients in the experimental group were treated with urokinase in the treatment of sudden deafness. The purpose of this study was to explore the clinical effect of Xueshuantong combined with urokinase in the treatment of sudden deafness.

2. Materials and Methods

2.1. Study Population. A total of 90 patients with sudden deafness who were treated in South China Hospital affiliated to Shenzhen University from June 2019 to August 2020 were recruited and assigned (1:1) into the control group (n = 45) and the experimental group (n = 45) according to the different treatment methods. The patients were informed about the study and signed the informed consent voluntarily.

2.2. Inclusion and Exclusion Criteria. The inclusion criteria were as follows: (1) the clinical diagnostic criteria for sudden deafness were met; (2) age 18–70 years old. The exclusion criteria were as follows: (1) patients with cardiovascular and cerebrovascular diseases and bleeding diseases; (2) patients with poorly controlled hypertension or diabetes; (3) those who had taken anticoagulant drugs within 1 month before enrollment; (4) pregnant and lactating women; (5) patients with severe liver and kidney insufficiency; and (6) patients with poor compliance who could not cooperate with this study.

2.3. Methods. Patients in the control group were treated with 200,000 IU urokinase (manufacturer: Guangzhou Putian Chemical Pharmaceutical Co., Ltd.; approval number: H44024035) [9] with 100 ml of normal saline, via intravenous infusion within 30 minutes, once a day. On the basis of the treatment in the control group, the patients in the experimental group were given 450 mg Xueshuantong injection (manufacturer: Guangxi Wuzhou Pharmaceutical Group Co., Ltd.; approval number: Z20025652) with 500 ml of 5% glucose injection via an intravenous drip, 1 time/d. Both groups were treated for 1 month.

2.4. Outcomes

(1) Clinical treatment efficiency: cured: the average hearing valve of the damaged frequency returns to the normal level; markedly effective: the average hearing valve of the damaged frequency is increased to more than 30 dB; improved: the average hearing valve of the damaged frequency is increased to 15–30 dB; ineffective: the condition does not meet the above standards or even aggravates. Total effective rate = (cured + markedly effective + improved)/total number of cases × 100%.

(2) Determination of the degree of tinnitus and the average auditory valve of the damaged frequency: according to the tinnitus environment, tinnitus duration, tinnitus impact on sleep, tinnitus impact on life and work, tinnitus impact on mood, and the overall feeling of patients with tinnitus, the score is 0~3 from light to severe. The higher the score, the more serious the damage.

(3) Hemorheology: 5 ml of fasting venous blood was drawn from patients before and after treatment, lithium heparin was used for anticoagulation, and an automatic hemorheology detector was used to detect the plasma viscosity, whole blood high-shear reduced viscosity, whole blood low-shear reduced viscosity, hematocrit, and fibrinogen index levels.

2.5. Statistical Analysis. The data analysis was performed using software SPSS20.0, measurement data are expressed as (X ± s), and the independent samples t-test was used for comparison; enumeration data are expressed as the number of cases (rate), and the chi-square test was used for comparison. Statistical significance was set at P < 0.05.

3. Results

3.1. General Data. The control group included 24 males and 21 females, the mean age was (52.57 ± 6.58) years, the mean disease duration was (3.79 ± 2.87) days, and 28 patients were unilateral and 17 bilateral. The experimental group included 25 males and 20 females, the average age was (52.72 ± 6.63) years, the average disease duration was (3.75 ± 2.91) days, and 26 cases were unilateral and 19 bilateral. There was no significant difference in baseline data between the two groups of patients, as shown in Table 1.

3.2. Clinical Treatment Effects. In the control group, there were 11 cases of cured, 16 cases of markedly effective, 9 cases of improved, and 9 cases of ineffective, with a total effective rate of 80% (36/45). In the experimental group, there were 27 cases of cured, 10 cases of markedly effective, 7 cases of improved, and 1 case of ineffective, with a total effective rate of 98% (44/45). The treatment with urokinase and Xueshuantong injection in the experimental group resulted in a significantly higher clinical treatment effect when compared with the treatment in the control group (P < 0.05, Table 2).
In addition, no significant adverse reactions were observed in either study group.

### 3.3. Tinnitus Degree and Damaged Frequency Average Listening Valve

Before treatment, the degree of tinnitus and the average auditory valve of the damaged frequency were comparable (all $P > 0.05$). After treatment, the above indicators were all decreased, and the much lower results were observed in the experimental group ($P < 0.05$, Table 3).

### 3.4. Hemorheology Indexes

The levels of hemorheology (plasma viscosity, whole blood high-shear reduced viscosity, whole blood low-shear reduced viscosity, hematocrit, and fibrinogen) were comparable between the two groups. After treatment, the above indicators were all decreased and lower in the experimental group ($P < 0.05$, Table 4).

### 4. Discussion

The results showed that the degree of tinnitus and the average auditory valve of the damaged frequency in the two groups were improved after treatment, which indicates that urokinase thrombolysis can relieve the symptoms of patients and is effective to improve the hearing of patients [14]. Urokinase is a commonly used thrombolytic drug in clinical practice and plays a role in thrombolyis [15]. However, the
effective dose of thrombolytic drugs presents individual differences, so it is challenging to accurately manage the dose in clinical practice, which results in poor efficacy in most cases. Possibly, the degradation of fibrinogen would lead to hyperfibrinolysis in the whole body, thus resulting in the digestive tract hemorrhage, cerebral hemorrhage, and other side effects [16]. According to the theory of TCM, sudden deafness is associated with the stagnation of qi and blood in the body and the obstruction of blood vessels. Armed with this knowledge, the combination of traditional Chinese medicine for promoting blood circulation and dredging collaterals might be a feasible strategy in clinical treatment of this disease [17]. According to the theory of TCM, it can significantly mitigate the symptoms of sudden deafness. Studies have confirmed that acupuncture points such as the Yifeng point contribute to enriching yin and purging fire so as to effectively promote the body ErCong intruders. Xueshuantong injection is made from the extract of traditional Chinese medicine, that is, Panax notoginseng. Its main active ingredient, Panax notoginseng saponins, can favorably promote blood circulation and remove blood stasis and has functions of antithrombotic and antiplatelet aggregation [18]. The findings of the present study showed that the clinical treatment effect of the patients in the experimental group was significantly superior to that in the control group, suggesting that Xueshuantong combined with urokinase produces a remarkable efficiency in the treatment of patients with sudden deafness. The possible explanation may be that the total saponins of Panax notoginseng in Xueshuantong can inhibit thrombin-induced platelet aggregation, thus inhibiting the formation of thrombus in the body. Also, it can scavenge oxygen free radicals, thereby inhibiting lipid peroxidation and alleviating the damage of ischemia-reperfusion in the body. All these reduce the damage to tissue and organ function caused by ischemia [19]. To the best of our knowledge, Xueshuantong in the treatment of deep vein thrombosis of the lower extremities could significantly reduce the blood viscosity of the patient [20]. Notably, we also compared the hemorheological indicators of the patients and found that Xueshuantong can effectively improve the hemorheological indexes of patients, which further consolidates its feasibility on thrombosis [21]. In this study, the Xueshuantong capsule has good safety, but the safety of long-term applications still needs investigation. However, there were still some limitations in this study. First, the long-term clinical outcomes were not assessed. Second, the blind method was not used in the study, which might result in bias due to subject and investigator factors. Third, the number of patients included in this study was small, which might compromise its generalization. In the future, randomized controlled studies with a large sample size and long follow-up are needed.

5. Conclusion

The clinical effect of Xueshuantong combined with urokinase in the treatment of patients with sudden deafness is remarkable, and its treatment method can effectively improve the hearing level and hemorheology-related indexes of patients, and it merits clinical application.

Data Availability

No data were used to support this study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] Y. H. Young, “Contemporary review of the causes and differential diagnosis of sudden sensorineural hearing loss,” International Journal of Audiology, vol. 59, no. 4, pp. 243–253, 2020.
[2] A. B. Bayoumy and J. A. de Ru, “Sudden deafness and tuning fork tests: towards optimal utilisation,” Practical Neurology, vol. 20, no. 1, pp. 66–68, 2020.
[3] B. J. Buckley, U. Ali, M. J. Kelso, and M. Ranson, “The urokinase plasminogen activation system in rheumatoid arthritis: pathophysiological roles and prospective therapeutic targets,” Current Drug Targets, vol. 20, no. 9, pp. 970–981, 2019.
[4] R. R. A. Kadir and U. Bayraktutan, “Urokinase plasminogen activator: a potential thrombolytic agent for ischaemic stroke,” Cellular and Molecular Neurobiology, vol. 40, no. 3, pp. 347–355, 2020.
[5] S. S. Lakka, C. S. Gondi, D. H. Dinh et al., “Retraction: specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas,” Journal of Biological Chemistry, vol. 295, no. 37, Article ID 13135, 2020.
[6] J. M. Leth and M. Floug, “Targeting the urokinase-type plasminogen activator receptor (uPAR) in human diseases with a view to non-invasive imaging and therapeutic intervention,” Frontiers in Cell and Developmental Biology, vol. 9, Article ID 732015, 2021.
[7] A. Li Santi, F. Napolitano, N. Montuori, and P. Ragni, “The urokinase receptor: a multifunctional receptor in cancer cell biology. therapeutic implications,” International Journal of Molecular Sciences, vol. 22, no. 8, p. 4111, 2021.
[8] A. S. Turk, A. Siddiqui, J. T. Fifi et al., “Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial,” The Lancet, vol. 393, no. 10175, pp. 998–1008, 2019.
[9] V. Metrangolo, M. Floug, and L. H. Engelholm, “The urokinase receptor (uPAR) as a ‘trojan horse’ in targeted cancer therapy: challenges and opportunities,” Cancers, vol. 13, no. 21, p. 5376, 2021.
[10] S. S. Chandrasekhar, B. S. Tsai Do, S. R. Schwartz et al., “Clinical practice guideline: sudden hearing loss (update),” Otolaryngology - Head and Neck Surgery, vol. 161, pp. S1–s45, 2019.
[11] Y. Sun, Y. Xing, X. Jiang et al., “Effectiveness of Ginkgo biloba diterpene lactone in the treatment of sudden sensorineural hearing loss,” American Journal of Otolaryngology, vol. 42, no. 3, Article ID 102922, 2021.
[12] R. Krishnan, W. Mays, and L. Elijovich, “Complications of mechanical thrombectomy in acute ischemic stroke,” Neurology, vol. 97, pp. S115–s125, 2021.

[13] M. Herrera, J. R. G. Berrocal, A. G. Arumi, M. J. Lavilla, and G. Plaza, “Update on consensus on diagnosis and treatment of idiopathic sudden sensorineural hearing loss,” Acta Otorrinolaringologica (English Edition), vol. 70, no. 5, pp. 290–300, 2019.

[14] J. P. Si, H. Jiang, and Y. Y. Li, “Correlation between effectual time and the curative effect in patients with all frequency descending sudden deafness after treatment,” American Journal of Otolaryngology, vol. 41, no. 5, Article ID 102621, 2020.

[15] M. Nabil, G. Chater, P. Correia, S. Wegener, and G. Baltsavias, “Thrombectomy-related emboli: direct aspiration versus stent retriever thrombectomy for acute ischemic stroke: our experience and literature review,” World Neurosurgery, vol. 135, pp. e588–e597, 2020.

[16] M. Yepes, “Urokinase-type plasminogen activator is a modulator of synaptic plasticity in the central nervous system: implications for neurorepair in the ischemic brain,” Neural Regeneration Research, vol. 15, no. 4, p. 620, 2020.

[17] S. R. Onteddu, P. Veerapaneni, K. Nalleballe et al., “Stroke transfers for thrombectomy in the era of extended time,” Clinical Neurology and Neurosurgery, vol. 200, Article ID 106371, 2021.

[18] H. T. Pan, J. J. Wang, J. L. Huang et al., “Ranibizumab plus Fufang Xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration,” Journal of International Medical Research, vol. 48, no. 9, Article ID 030006052093161, 2020.

[19] A. I. Qureshi, B. Singh, W. Huang et al., “Mechanical thrombectomy in acute ischemic stroke patients performed within and outside clinical trials in the United States,” Neurosurgery, vol. 87, p. S24, 2020.

[20] H. Li, B. Li, and Y. Zheng, “Exploring the mechanism of action compound-Xueshuantong capsule in diabetic retinopathy treatment based on network pharmacology,” Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 8467046, 12 pages, 2020.

[21] E. J. Formeister, W. Chien, Y. Agrawal, J. P. Carey, C. M. Stewart, and D. Q. Sun, “Preliminary analysis of association between COVID-19 vaccination and sudden hearing loss using US centers for disease control and prevention vaccine adverse events reporting system data,” JAMA Otolaryngology-- Head & Neck Surgery, vol. 147, no. 7, pp. 674–676, 2021.